Serum free light chains, interferon-alpha, and interleukins in systemic lupus erythematosus

Lupus

Volumn 23, Issue 9, 2014, Pages 881-888

  Jolly, M ^a   Francis, S ^b   Aggarwal, R ^c   Mikolaitis, R A ^a   Niewold, T B ^d   Chubinskaya, S ^a   Block, J A ^a   Scanzello, C ^a   Sequeira, W ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b CENTRAL DUPAGE HOSPITAL   (United States)

^c UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

biomarkers; free light chains (FLCs); Systemic lupus erythematosus (SLE)

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; INTERLEUKIN 10; INTERLEUKIN 6; METHOTREXATE; MYCOPHENOLIC ACID; PREDNISONE; ANTINUCLEAR ANTIBODY; IL10 PROTEIN, HUMAN; IL6 PROTEIN, HUMAN;

ADULT; ARTICLE; BODY MASS; CONTROLLED STUDY; DISEASE ACTIVITY; ETHNICITY; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIGHT CHAIN; MAJOR CLINICAL STUDY; MALE; MEDIATOR RELEASE; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCORING SYSTEM; SLEDAI; SYSTEMIC LUPUS ERYTHEMATOSUS; BLOOD; CROSS-SECTIONAL STUDY; IMMUNOLOGY; MIDDLE AGED;

ADULT; ANTIBODIES, ANTINUCLEAR; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; IMMUNOGLOBULIN KAPPA-CHAINS; IMMUNOGLOBULIN LAMBDA-CHAINS; INTERFERON-ALPHA; INTERLEUKIN-10; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED;

EID: 84903758257     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314530793     Document Type: Article

References (47)

1. Hopper JE, Papagiannes E. Evidence by radioimmunoassay that mitogen-activated human blood mononuclear cells secrete significant amounts of light chain Ig unassociated with heavy chain. Cell Immunol. 1986 ; 101: 122-131
2. Hopper JE, Sequeira W, Martellotto J, et al. Clinical relapse in systemic lupus erythematosus: correlation with antecedent elevation of urinary free light chain immunoglobulin. J Clin Immunol. 1989 ; 9: 338-350
3. Aggarwal R, Sequeira W, Kokebie R, et al. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity. Arthritis Care Res (Hoboken). 2011 ; 63: 891-898
4. Jolly M, Aggarwal R, Francis S, et al. Serum free light chains and disease activity in systemic lupus erythematosus. Hematol Rep. 2010 ; 2 (s2). 45-45
5. Guillemette T, Bardin N, Cournac J, et al. Serum free light chain levels as a marker of disease activity following treatment with B cell depletion in systemic lupus erythematosus. Hematol Rep. 2010 ; 2 (s2). 44-44
6. Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clones: definition according to profiles of lymphokines and secreted proteins. J Immunol. 1986 ; 136: 2348-2357
7. Akahoshi M, Nakashima H, Tanaka Y, et al. Th1/Th2 balance of peripheral T cells in SLE. Arthritis Rheum. 1999 ; 42: 1644-1648
8. Ishida H, Muchamuel T, Sakaguchi S, et al. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W mice. J Exp Med. 1994 ; 179: 305-310
9. Racke MK, Bonomo A, Scott DE, et al. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp Med. 1994 ; 180: 1961-1966
10. Takahashi S, Fossati L, Iwamoto M, et al. Imbalance towards Th1 predominance is associated with acceleration of lupus like autoimmune syndrome in MRl mice. J Clin Invest. 1996 ; 97: 1597-1604
11. Dayan M, Segal R, Mozes E. Cytokine manipulation by methotrexate treatment in murine experimental SLE. J Rheumatol. 1997 ; 24: 1075-1082
12. Kishimoto T, Hirano T. Molecular regulation of the B cell lymphocyte response. Annu Rev Immunol. 1988 ; 6: 485-512
13. Van Snick J. Interleukin-6: an overview. Annu Rev Immunol. 1990 ; 8: 253-278
14. Nagafuchi H, Suzuki N, Mizushima Y, et al. Constitutive expression of IL-6 receptors and their role in the excessive B cell function in patients with systemic lupus erythematosus. J Immunol. 1993 ; 151: 6525-6534
15. Kawano MM, Mihara K, Huang N, et al. Differentiation of early plasma cells on bone marrow stromal cells requires IL-6 for escaping from apoptosis. Blood. 1995 ; 85: 487-494
16. Linker-Israeli M, Deans RJ, Wallace DJ, et al. Elevated levels of endogenous IL-6 in systemic lupus erythematosus - a putative role in pathogenesis. J Immunol. 1991 ; 147: 117 123-123
17. Suh CH, Kim HA. Cytokines and their receptors as biomarkers for systemic lupus erythematosus. Expert Rev Mol Diagn. 2008 ; 8: 189-198
18. Chun HY, Chung JW, Kim HA, et al. Cytokine IL-6 and IL-10 as biomarkers in SLE. J Clin Immunol. 2007 ; 27: 461-466
19. Moore KW, O'Garra A, Malefyt RW, et al. Interleukin 10. Annu Rev Immunol. 1993 ; 11: 165-190
20. Firentino DF, Bond MW, Mosmann TR. Two types of mouse T helper cells. IV TH2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 1989 ; 170: 2081-2095
21. Hsu DH, Moore KW, Spits H. Differential effects of IL-4 and IL-10 on IL-2-induced IFN-γ synthesis and lymphokine activated killer activity. Int Immunol. 1992 ; 4: 563-569
22. Rousset F, Garcia E, Defrance T, et al. IL-10 is a potent growth and differentiation factor for activated human B lymphocytes. Proc Natl Acad Sci USA. 1992 ; 89: 1890-1893
23. Viallard JF, Pellegrin JL, Ranchin V, et al. Th1 (IL-2, interferon-gamma (IFN-γ)) and Th2 (IL-10, IL-4) cytokine production by peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1999 ; 115: 189-195
24. Blanco P, Palucka AK, Gill M, et al. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science. 2001 ; 294: 1540-1543
25. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999 ; 284: 1835-1837
26. Kirou KA, Lee C, George S, et al. Activation of the interferon-α pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease. Arthritis Rheum. 2005 ; 52: 1491-1503
27. Niewold TB, Hua J, Lehman TJ, et al. High serum IFN-α activity is a heritable risk factor for systemic lupus erythematosus. Genes Immun. 2007 ; 8: 492-502
28. Kariuki SN, Niewold TB. Genetic regulation of serum cytokines in systemic lupus erythematosus. Transl Res. 2010 ; 155(3): 109-117
29. Kariuki SN, Franek BS, Kumar AA, et al. Trait-stratified genome-wide association study identifies novel and diverse genetic associations with serologic and cytokine phenotypes in systemic lupus erythematosus. Arthritis Res Ther. 2010 ; 12: R151 - R151
30. Baechler EC, Batliwalla FM, Karypis G, et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA. 2003 ; 100: 2610-2615
31. Petri M, Singh S, Tesfasyone H, et al. Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus. 2009. 18: 980-989
32. Landolt-Marticorena C, Bonventi G, Lubovich A, et al. Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis. 2009 ; 68: 1440-1446
33. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982 ; 25: 1271-1277
34. Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI: a disease activity index for lupus patients. The committee on prognosis studies in SLE. Arthritis Rheum. 1992 ; 35: 630-640
35. Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free κ and free immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002 ; 48: 1437-1444
36. Bradwell AR Serum free light chain analysis. 5 th ed. Rhondda: HSK Ltd, 2008. Rhondda: HSK Ltd ; 2008 :
37. Hua J, Kirou K, Lee C, Crow MK. Functional assay of type I interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies. Arthritis Rheum. 2006 ; 54: 1906-1916
38. Metsärinne KP, Nordström DC, Konttinen YT, et al. Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int. 1992 ; 12: 93-96
39. Swaak AJ, Rooyen A, Aarden LA. Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus. Rheumatol Int. 1989 ; 8: 263-268
40. Spronk PE, Borg EJ, Limburg PC, Kallenberg CG. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity?. Clin Exp Immunol. 1992 ; 90: 106-110
41. Grondal IG, Gunnarsson I, Rönnelid J, et al. Cytokine production, serum levels and disease activity in systemic lupus erythematosus. Clin Exp Rheumatol. 2000 ; 18: 565-570
42. Peterson E, Robertson AD, Emlen W. Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus. 1996 ; 5: 571-575
43. Houssiau FA, Lefebvre C, Vanden Berghe M, et al. Serum interleukin-10 titers in systemic lupus erythematosus reflect disease activity. Lupus. 1995 ; 5: 393-395
44. Dhir V, Singh AP, Aggarwal A, et al. Increased T-lymphocyte apoptosis in lupus correlates with disease activity and may be responsible for reduced T-cell frequency: a cross-sectional and longitudinal study. Lupus. 2009 ; 18: 785-791
45. Zhang R, Xing M, Ji X, et al. Interferon-α and interleukin-6 in SLE serum induce the differentiation and maturation of dendritic cells derived from CD34+ hematopoetic precursor cells. Cytokine. 2010 ; 50: 195-203
46. Lodolce JP, Kolodziej LE, Rhee L, et al. African-derived genetic polymorphisms in TNFAIP3 mediate risk for autoimmunity. J Immunol. 2010 ; 184: 7001-7009
47. Bauer JW, Baechler EC, Petri M, Batliwalla FM, et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med. 2006 ; 3: e491 - e491